Drug maker Pfizer Inc. has reached an $894 million deal to settle most of the lawsuits over its withdrawn pain reliever Bextra, following the lead of rival Merck & Co., which is spending five times as much to settle Vioxx suits. The agreement also would end lawsuits over Pfizer's Celebrex, the only one of the three anti-inflammatory drugs still on the market. All three products have been linked to elevated risk of heart attacks and strokes.
$894 Million Deal Ends Pain of Pfizer's Lawsuits
The Associated Press
October 20, 2008